Molecular Partners (MOLN) Competitors

Phibro Animal Health (NASDAQ:PAHC) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.

Do insiders & institutionals have more ownership in PAHC or MOLN?

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 26.6% of Molecular Partners shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 5.9% of Molecular Partners shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor PAHC or MOLN?

Phibro Animal Health received 302 more outperform votes than Molecular Partners when rated by MarketBeat users. Likewise, 60.15% of users gave Phibro Animal Health an outperform vote while only 46.15% of users gave Molecular Partners an outperform vote.

Company	Underperform	Outperform
Phibro Animal Health	Outperform Votes 314 60.15%	Underperform Votes 208 39.85%
Molecular Partners	Outperform Votes 12 46.15%	Underperform Votes 14 53.85%

Which has more volatility & risk, PAHC or MOLN?

Phibro Animal Health has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Does the media prefer PAHC or MOLN?

In the previous week, Phibro Animal Health had 5 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Phibro Animal Health and 2 mentions for Molecular Partners. Phibro Animal Health's average media sentiment score of 0.85 beat Molecular Partners' score of 0.37 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Molecular Partners	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts recommend PAHC or MOLN?

Phibro Animal Health presently has a consensus target price of $20.50, indicating a potential downside of 6.73%. Given Phibro Animal Health's higher possible upside, equities analysts plainly believe Phibro Animal Health is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Molecular Partners	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Is PAHC or MOLN more profitable?

Phibro Animal Health has a net margin of 1.67% compared to Molecular Partners' net margin of -1,043.01%. Phibro Animal Health's return on equity of 21.59% beat Molecular Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	1.67%	21.59%	5.85%
Molecular Partners	-1,043.01%	-39.31%	-35.46%

Which has preferable valuation and earnings, PAHC or MOLN?

Phibro Animal Health has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.02B	0.87	$2.42M	$0.43	51.12
Molecular Partners	$7.84M	26.90	-$69.04M	-$2.15	-2.43

Summary

Phibro Animal Health beats Molecular Partners on 14 of the 18 factors compared between the two stocks.